title: Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment.
abstract: This study explores whether near-infrared (NIr) light treatment neuroprotects dopaminergic cells in the substantia nigra pars compacta (SNc) and the zona incerta-hypothalamus (ZI-Hyp) from degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. BALB/c albino mice were divided into four groups: 1) Saline, 2) Saline-NIr, 3) MPTP, 4) MPTP-NIr. The injections were intraperitoneal and they were followed immediately by NIr light treatment (or not). Two doses of MPTP, mild (50 mg/kg) and strong (100 mg/kg), were used. Mice were perfused transcardially with aldehyde fixative 6 days after their MPTP treatment. Brains were processed for tyrosine hydroxylase (TH) immunochemistry. The number of TH(+) cells was estimated using the optical fractionator method. Our major finding was that in the SNc there were significantly more dopaminergic cells in the MPTP-NIr compared to the MPTP group (35%-45%). By contrast, in the ZI-Hyp there was no significant difference in the numbers of cells in these two groups. In addition, our results indicated that survival in the two regions after MPTP insult was dose-dependent. In the stronger MPTP regime, the magnitude of loss was similar in the two regions ( approximately 60%), while in the milder regime cell loss was greater in the SNc (45%) than ZI-Hyp ( approximately 30%). In summary, our results indicate that NIr light treatment offers neuroprotection against MPTP toxicity for dopaminergic cells in the SNc, but not in the ZI-Hyp.
authors.affiliation: Discipline of Anatomy & Histology F13, University of Sydney, Australia.
authors.forename: Victoria E
authors.initials: VE
authors.lastname: Shaw
authors.forename: Sharon
authors.initials: S
authors.lastname: Spana
authors.forename: Keyoumars
authors.initials: K
authors.lastname: Ashkan
authors.forename: Alim-Louis
authors.initials: AL
authors.lastname: Benabid
authors.forename: Jonathan
authors.initials: J
authors.lastname: Stone
authors.forename: Gary E
authors.initials: GE
authors.lastname: Baker
authors.forename: John
authors.initials: J
authors.lastname: Mitrofanis
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D006801:Humans; D007259:Infrared Rays; D020267:MPTP Poisoning / Q000473:pathology / Q000628:therapy; D008297:Male; D008636:Mesencephalon / Q000166:cytology / Q000187:drug effects / Q000528:radiation effects; D051379:Mice; D008807:Mice, Inbred BALB C; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000528:radiation effects; D018696:Neuroprotective Agents; D009498:Neurotoxins / Q000494:pharmacology; D010300:Parkinson Disease / Q000503:physiopathology; D010789:Phototherapy; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects / Q000528:radiation effects; D020530:Subthalamus / Q000166:cytology / Q000187:drug effects / Q000528:radiation effects; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D015259:Dopamine Agents; D018696:Neuroprotective Agents; D009498:Neurotoxins; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine